Intellipharmaceutics International Inc. - 20-F filing on 2022-04-01

Options (Tables)

12 Months Ended

Nov. 30, 2021

Schedule of share-based payment award, stock options, valuation assumptions

		November 30,				November 30,				November 30,
		2021				2020				2019

Volatility			-				-				93.90% - 111.93	%
Risk-free interest rate			-				-				1.62% - 1.90	%
Expected life (in years)			-				-				5.78 - 10.00
Dividend yield			-				-				-
The weighted average grant date fair value of options granted			-				-			$	0.22 - $0.28

Schedule of share-based compensation, stock options, activity

		November 30, 2021												November 30, 2020												November 30, 2019
						Weighted												Weighted												Weighted
						average				Weighted								average				Weighted								average				Weighted
						exercise				average								exercise				average								exercise				average
		Number of				price per				grant date				Number of				price per				grant date				Number of				price per				grant date
		options				share				fair value				options				share				fair value				options				share				fair value
							$				$								$				$								$				$
Outstanding, beginning of year			1,697,638				2.92				1.99				2,353,829				8.35				4.30				555,651				37.70				19.33
Granted			-				-				-				-				-				-				1,887,000				0.35				0.26
Cancelled			(156,572	)			1.05				0.57				(101,182	)			1.53				0.78				-				-				-
Forfeiture			(6,666	)			0.35				0.22				(225,315	)			0.35				0.22				(28,432	)			1.41				0.80
Expired			(44,900	)			27.60				13.74				(329,694	)			42.84				19.68				(60,390	)			31.54				14.27
Balance, end of year			1,489,500				2.40				1.80				1,697,638				2.92				1.99				2,353,829				8.35				4.30

Options exercisable, end of year			1,489,500				2.40				1.80				1,231,309				3.90				2.64				1,122,189				17.12				8.75

Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range

		Options outstanding																Options exercisable
						Weighted				Weighted				Weighted								Weighted				Weighted
						average				average				average								average				average
						exercise				remaining				grant								exercise				grant
Exercise		Number				price per				contract				date				Number				price per				date
price		outstanding				share				life (years)				fair value				exercisable				share				fair value
$						$								$								$				$
Under 25			1,404,500				0.55				7.19				0.38				1,404,500				0.55				0.38
26.00 - 50.00			85,000				32.70				0.21				25.08				85,000				32.70				25.08
			1,489,500				2.40												1,489,500				0.12				-

Schedule of employee service share-based compensation, allocation of recognized period costs

		November 30,				November 30,				November 30,
		2021				2020				2019
						$				$
Research and development			9,719				60,446				212,357
Selling, general and administrative			2,266				11,199				52,211
			11,985				71,645				264,568